Physician profile
Arthur Sudan
NPI 1225002389
$2,889.68
in general payments reported to CMS, 2019-2025
29 companies · $677 in 2025
The $677 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2022: $14.77 · 2023: $282 · 2024: $907 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $370.61 | 2019-2025 | |
| Novo Nordisk INC | $329.66 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Shield Therapeutics INC | $253.48 | 2023-2025 | Accrufer |
| Glaxosmithkline, LLC. | $225.45 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $220.44 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $186.64 | 2019-2025 | Otezla, Repatha, Evenity |
| Astellas Pharma US INC | $160.99 | 2019-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.56 | 2019-2024 | Jardiance |
| Lundbeck LLC | $101.62 | 2023-2025 | Rexulti |
| Abbvie INC. | $89.77 | 2019-2024 | |
| Amarin Pharma, INC. | $88.00 | 2019 | |
| Dexcom, INC. | $86.15 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $84.47 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $82.90 | 2019-2025 | Jardiance |
| Abbott Laboratories | $65.91 | 2022-2025 | Eterna |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $63.35 | 2019-2025 | Capvaxive, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.14 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $54.86 | 2023-2025 | Eliquis |
| Janssen Pharmaceuticals, INC | $48.57 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.48 | 2024-2025 | |
| Vanda Pharmaceuticals INC. | $26.23 | 2024 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $22.60 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $17.71 | 2025 | Auvelity |
| Aimmune Therapeutics, INC. | $15.72 | 2024 | |
| Sanofi Pasteur INC. | $13.74 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.50 | 2019 | |
| Radius Health, INC. | $12.41 | 2019 | |
| Genentech USA, INC. | $12.40 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Sudan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.